[go: up one dir, main page]

WO2020125776A1 - 式(iv)化合物的工艺路线、晶型及其制备方法 - Google Patents

式(iv)化合物的工艺路线、晶型及其制备方法 Download PDF

Info

Publication number
WO2020125776A1
WO2020125776A1 PCT/CN2019/127155 CN2019127155W WO2020125776A1 WO 2020125776 A1 WO2020125776 A1 WO 2020125776A1 CN 2019127155 W CN2019127155 W CN 2019127155W WO 2020125776 A1 WO2020125776 A1 WO 2020125776A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
crystal form
solvent
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/127155
Other languages
English (en)
French (fr)
Inventor
罗志
李小林
杨亚讯
杨乐乐
李鹏
贺海鹰
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Danhong Pharmaceutical Co Ltd
Original Assignee
Shandong Danhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Danhong Pharmaceutical Co Ltd filed Critical Shandong Danhong Pharmaceutical Co Ltd
Priority to ES19897902T priority Critical patent/ES2981573T3/es
Priority to JP2021536243A priority patent/JP7245911B2/ja
Priority to CN201980066989.7A priority patent/CN112823154A/zh
Priority to US17/311,431 priority patent/US12077513B2/en
Priority to KR1020217022942A priority patent/KR102583801B1/ko
Priority to AU2019408509A priority patent/AU2019408509B2/en
Priority to EP19897902.3A priority patent/EP3901143B1/en
Publication of WO2020125776A1 publication Critical patent/WO2020125776A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention discloses a technological route, a crystal form of the compound of formula (IV) and a preparation method thereof, and further includes the application of the crystal form in preparing a medicine for treating diseases related to SSAO.
  • amine oxidases In most organisms including humans, two groups of mammalian amine oxidases metabolize various monoamine-, diamine-, and polyamines produced endogenously or absorbed from exogenous sources. These include monoamine oxidases (MAO-A and MAO-B) that are present in most cell types of mitochondria and use covalently bound flavin adenine dinucleotide (FAD) as a cofactor.
  • FAD flavin adenine dinucleotide
  • Polyamine oxidase is another FAD-dependent amine oxidase that oxidizes deaminospermidine and spermidine.
  • SSAO/VAP-1 belongs to the copper-dependent second group and uses other cofactors such as oxidized tyrosine residues (abbreviated as TPQ or LTQ) in addition to FAD. Oxidative deamination of MAO and SSAO/VAP-1 includes some common substrates for monoamines such as dopamine, tyramine and benzylamine. SSAO/VAP-1 also oxidizes endogenous methylamine and aminoacetone.
  • SSAO Semicarbazide-sensitive amine oxidase
  • VAP-1 vascular adhesion protein-1
  • MAO-A is selectively inhibited by chlorgilin and MAO-B is selectively inhibited by L-benzylmethanamine, although neither chlorgilin nor L-benzylmethinamine can inhibit the amine oxidase of SSAO/VAP-1 active.
  • SSAO/VAP-1 can be inhibited by semicarbazide, hence the name semicarbazide-sensitive amine oxidase.
  • SSAO/VAP-1 is an extracellular enzyme that contains a very short cytoplasmic tail, a single transmembrane domain, and a large highly glycosylated extracellular domain that contains an active center for amine oxidase activity.
  • SSAO/VAP-1 also exists in a dissolved form circulating in the plasma of some animals. This form has been shown to be a cleavage product of membrane-bound SSAO/VAP-1.
  • SSAO/VAP-1 appears to have two physiological functions: the first is the aforementioned amine oxidase activity and the second is the cell adhesion activity. Both activities are related to inflammatory processes.
  • SSAO/VAP-1 has been shown to play an important role in the extravasation of circulating inflammatory cells from the site of inflammation.
  • VAP-1 antibody has been shown to attenuate the inflammatory process by blocking the adhesion sites of SSAO/VAP-1 protein, and provides a large amount of evidence for knockout in vitro and in vivo. It is now clear that SSAO/VAP-1 is an important inflammatory cell Mediator.
  • WO2013163675 reports the compound PXS-4728A, whose structure is as follows.
  • the present invention provides Form A of the compound of formula (IV), whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 9.05 ⁇ 0.2°, 12.34 ⁇ 0.2°, 22.52 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound of formula (IV) above has characteristic diffraction peaks at the following 2 ⁇ angles: 9.05 ⁇ 0.2°, 12.34 ⁇ 0.2°, 16.60 ⁇ 0.2°, 17.17 ⁇ 0.2°, 17.83 ⁇ 0.2°, 20.82 ⁇ 0.2°, 22.52 ⁇ 0.2°, 26.03 ⁇ 0.2°.
  • the XRPD pattern of Form A of the compound of formula (IV) is shown in FIG. 1.
  • Form A of the compound of formula (IV) above has a differential scanning calorimetry curve with a peak endothermic peak at 223.0°C ⁇ 3.0°C.
  • the DSC chart of Form A of the compound of formula (IV) is shown in FIG. 2.
  • thermogravimetric analysis curve of Form A of the compound of formula (IV) above has a weight loss of 3.78% at 150.0°C ⁇ 3°C.
  • the TGA pattern of Form A of the compound of formula (IV) above is shown in FIG. 3.
  • the invention also provides a method for preparing the crystalline form A of the compound of formula (IV), including adding any one of the compounds of formula (IV) to an organic solvent mixture of esters and ethers, wherein the beating temperature is selected From 20°C ⁇ 40°C.
  • the above-mentioned ester-based solvent is selected from ethyl acetate, and the ether-based solvent is selected from methyl tert-butyl methyl ether.
  • the beating time is selected from 30 hours to 60 hours.
  • the weight-volume ratio of the compound of formula (IV) to the organic mixed solvent is selected from 1:5 to 40.
  • the invention also provides Form B of the compound of formula (IV), whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 11.27 ⁇ 0.2°, 21.44 ⁇ 0.2°, 22.32 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound of formula (IV) above has characteristic diffraction peaks at the following 2 ⁇ angles: 11.27 ⁇ 0.2°, 12.46 ⁇ 0.2°, 18.44 ⁇ 0.2°, 21.44 ⁇ 0.2°, 22.32 ⁇ 0.2°, 25.51 ⁇ 0.2°, 25.94 ⁇ 0.2°, 26.49 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound of formula (IV) above has characteristic diffraction peaks at the following 2 ⁇ angles: 11.27 ⁇ 0.2°, 12.46 ⁇ 0.2°, 18.44 ⁇ 0.2°, 20.03 ⁇ 0.2°, 21.44 ⁇ 0.2°, 22.32 ⁇ 0.2°, 23.37 ⁇ 0.2°, 24.19 ⁇ 0.2°, 25.51 ⁇ 0.2°, 25.94 ⁇ 0.2°, 26.49 ⁇ 0.2°, 28.12 ⁇ 0.2°.
  • the XRPD pattern of the crystalline form B of the compound of formula (IV) is shown in FIG. 4.
  • the crystalline form B of the compound of formula (IV) above has a peak value of the endothermic peak at 221.9°C ⁇ 3.0°C.
  • the DSC chart of the above-mentioned compound of formula (IV) in Form B is shown in FIG. 5.
  • thermogravimetric analysis curve of Form B of the compound of formula (IV) above has a weight loss of 1.05% at 150.0°C ⁇ 3°C.
  • the TGA pattern of Form B of the compound of formula (IV) above is shown in FIG. 6.
  • the invention also provides a method for preparing the crystalline form B of the compound of formula (IV), which comprises adding any compound of formula (IV) to esters, ethers, alcohols, acetone, acetonitrile, n-heptane, water , Organic mixed solvent and water and organic mixed solvent beating, wherein the beating temperature is selected from 40 °C ⁇ 60 °C.
  • the preparation method of the crystalline form B of the compound of formula (IV) above wherein the ester solvent is selected from ethyl acetate, the ether solvent is selected from tetrahydrofuran and methyl tert-butyl ether, and the alcohol solvent is selected From ethanol, the organic mixed solvent is selected from the mixed solvent of methyl tert-butyl ether and methanol in a volume ratio of 95:5 and the mixed solvent of methyl tert-butyl ether and ethanol in a volume ratio of 95:5, water and organic mixture
  • the solvent is selected from a mixed solvent of water and acetone in a volume ratio of 5:95, a mixed solvent of water and acetonitrile in a volume ratio of 5:95, and a mixed solvent of water and tetrahydrofuran in a volume ratio of 5:95.
  • the beating time is selected from 30 hours to 60 hours.
  • the weight to volume ratio of the compound of formula (IV) to the organic mixed solvent is selected from 1:5 to 40.
  • the invention also provides the application of the above crystal form A or crystal form B in the preparation of a medicine for treating SSAO related diseases.
  • the aforementioned SSAO-related disease is non-alcoholic steatohepatitis.
  • the invention also provides a preparation method of the compound of formula (IV),
  • Solvent a is selected from acetic acid
  • Reagent b is selected from hydrochloric acid.
  • the volume of solvent a and SM1: mass is 3.0-3.5:1, and the volume of reagent b and SM1: mass is 3.0-10:1.
  • the reaction internal temperature is controlled to 75-80°C.
  • the method for preparing the compound of formula (IV) above includes the following steps:
  • the method for preparing the compound of formula (IV) above wherein reagent c is selected from pyridine; compound D is prepared by a hydrolysis reaction under alkaline conditions; reagent d is selected from potassium bromide and reagent e is selected from Sodium hypochlorite; reagent f is selected from silver acetate.
  • the crystal form A and B form of the compound of formula (IV) of the present invention have good stability.
  • the compound of formula (IV) and the crystalline form B of the compound of formula (IV) showed strong activity of inhibiting human recombinant VAP-1/SSAO enzyme and activity of inhibiting VAP-1/SSAO cells in in vitro tests.
  • the intermediate compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by the combination with other chemical synthesis methods, and those skilled in the art. Well-known equivalent alternatives, preferred embodiments include but are not limited to the examples of the present invention.
  • the compound of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art. For example, single crystal X-ray diffraction (SXRD), the cultured single crystal is collected with Bruker D8 venture diffractometer to diffract intensity data, the light source is CuK ⁇ radiation, and the scanning mode is: After scanning and collecting relevant data, the crystal structure can be further analyzed by the direct method (Shelxs97) to confirm the absolute configuration.
  • SXRD single crystal X-ray diffraction
  • the cultured single crystal is collected with Bruker D8 venture diffractometer to diffract intensity data
  • the light source is CuK ⁇ radiation
  • the scanning mode is: After scanning and collecting relevant data, the crystal structure can be further analyzed by the direct method (Shelxs97) to confirm the absolute configuration.
  • DMF stands for dimethylformamide
  • DCM stands for dichloromethane
  • DMSO dimethyl sulfoxide
  • MeOH stands for methanol
  • MsOH stands for methanesulfonic acid
  • EtOH stands for ethanol
  • NaOH stands for sodium hydroxide
  • TEA Stands for triethylamine
  • HCl stands for hydrochloric acid
  • Tol stands for toluene
  • KOH stands for potassium hydroxide
  • TEBAC stands for benzyltriethylammonium chloride
  • KBr stands for potassium bromide
  • NaHCO 3 stands for sodium bicarbonate
  • NaClO stands for sodium hypochlorite
  • TEMPO stands for 2 ,2,6,6-Tetramethylpiperidine oxide
  • Na 2 S 2 O 3 represents sodium thiosulfate
  • AcOH represents acetic acid
  • NMP represents N-methylpyrrolidone
  • AgOAc represents silver acetate
  • Test method about 10 ⁇ 20mg sample is used for XRPD detection.
  • Light tube voltage 40kV
  • light tube current 40mA
  • Anti-scattering slit 7.10mm
  • DSC Differential Scanning Calorimeter
  • Test method Take a sample (about 1mg) and put it in a DSC aluminum pan for testing. Under 50mL/min N 2 conditions, with a heating rate of 10°C/min, heat the sample from 30°C (room temperature) to 300°C (or 350 °C).
  • Thermogravimetric analysis (Thermal Gravimetric Analyzer, TGA) method of the present invention
  • Test method Take a sample (2 ⁇ 5mg) and place it in a TGA platinum pot for testing. Under the condition of 25mL/min N 2 and a heating rate of 10°C/min, heat the sample from room temperature to 350°C or lose 20% of weight.
  • Fig. 1 is an XRPD spectrum of Cu-K ⁇ radiation of Form A of the compound of formula (IV).
  • Fig. 3 is a TGA diagram of Form A of the compound of formula (IV).
  • Fig. 4 is an XRPD spectrum of Cu-K ⁇ radiation of Form B of the compound of formula (IV).
  • Fig. 5 is a DSC chart of Form B of the compound of formula (IV).
  • Fig. 6 is a TGA diagram of Form B of the compound of formula (IV).
  • step 1
  • the aqueous phase was extracted with ethyl acetate (1L*2), and the organic phases were combined.
  • the organic phase was washed with saturated brine (2L*2) and separated.
  • the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product.
  • reaction solution was transferred to a desktop filter with a peristaltic pump, suction filtered, and the filter cake was washed with 5L of n-heptane. Collect the filter cake to a clean tray and let it dry naturally for >24 hours. Compound F is obtained.
  • the filter cake was washed twice with water (2 L), and suction filtration was continued until no filtrate was produced.
  • the mixed solution was reacted at 90-95°C for 48h, and a sample was taken. When the residual amount of SM1 was less than 2.0%, the reaction was stopped.
  • the reaction solution was cooled to 0-10°C, filtered, and the filter cake was washed twice with 5 L of water to obtain a crude product.
  • the crude product was added to acetonitrile (8L), warmed to 50-55°C, and stirred for 3 hours. Filter while hot, collect the filter cake, and place the filter cake in a fume hood at 25-30°C for 24 hours to obtain compound 1.
  • the reaction liquid was cooled to 20-25°C, ethyl acetate (6.85L) was added to the reaction liquid for dilution, activated carbon (543g) and diatomaceous earth (543g) were added, and after stirring for 20 minutes, the silica gel (543g) was filtered and filtered with acetic acid The filter cake was washed three times with ethyl acetate (6.85L). The filtrate was washed twice with 10% sodium thiosulfate solution (6.85L), once with 0.5M sodium hydroxide solution (6.85L), and twice with clean water (6.85L), and the organic phase was dried under reduced pressure to obtain a crude product .
  • the crude product was dissolved in 3N hydrochloric acid (6L), and the aqueous solution was extracted once with methyl tert-butyl ether (6L) and twice with ethyl acetate (6L). Adjust the aqueous solution with 1M sodium hydroxide solution to pH>10, extract twice with methyl tert-butyl ether (6L), combine the organic phases, filter the insolubles in the organic phase, and spin-dry the organic phase under reduced pressure.
  • the organic phase was dissolved with 2-MeTHF solution (6L), washed once with 0.5M sodium hydroxide solution (6L) and twice with water (6L). The organic phase was collected and the organic phase was dried under reduced pressure.
  • the compound of formula (IV) (50 mg) was added to methyl tert-butyl methoxide (1 mL), and the slurry was beaten at 50°C for 48 hours. After cooling to 20-25°C, it was filtered, the solid was collected, and vacuum dried at 40°C for 48 hours to obtain Form B of the compound of formula (IV).
  • the crystalline form B of the compound of formula (IV) has good stability under the conditions of high temperature, high humidity and strong light.
  • VAP-1 enzyme activity uses Red Monoamine Oxidase kit (Invitrogen #A12214) measures the inhibitory effect of samples on VAP-1 enzyme activity.
  • a substrate mixture of VAP-1 enzyme 200 ⁇ M Amplex Red, 1 U/mL HRP, 1 mM Benzylamine was added, and incubated at room temperature for 60 minutes. After the incubation, the fluorescence signal was read with the microplate reader Envision (excitation light wavelength 530-560nm, emission light wavelength 590nm). Analysis using Prism software after removal of the signal value of the background fluorescence signal of the sample is calculated VAP-1 enzyme IC 50.
  • Red Monoamine Oxidase kit (Invitrogen #A12214) measures the inhibitory effect of samples on VAP-1 enzyme activity.
  • the cultured HUVEC or CHO cells were plated to a 6-well plate at a density of 0.8M/well, placed in a 37°C, 5% CO 2 incubator for 24 hours, and then transformed with Lipo2000 reagent and VAP-1/pCDNA (3.1) plasmid. After staining the cells, change the cells after 5h (Lipo2000 is toxic to the cells); after 24h, digest the cells and plate them into 384-well plates at a density of 25 ⁇ l, 10000cells/well, and change the cells with FBS-free medium for 6-7h. The cell plate was placed in a 5% CO 2 incubator at 37°C overnight.
  • Dilution of compound serial dilution of 4-fold gradient with 100% DMSO, diluted 10 points, the initial concentration of the test compound is 0.5mM (final concentration is 1 ⁇ M); use ECHO to transfer 100nl compound solution to 384-well cells for detection In the board.
  • Negative control well 100nl DMSO; background control well: 100nl DMSO + 25 ⁇ l medium.
  • the excitation wave is 535 nm and the emission wave is 590 nm.
  • Inhibition rate calculation formula:% Inhibition rate (1-(test hole minus background-positive control hole minus background)/(negative control hole minus background-positive control hole minus background))*100

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

公开了式(IV)化合物的工艺路线、晶型及其制备方法，还公开了所述晶型在制备治疗与SSAO相关疾病药物中的应用。

Description

式(IV)化合物的工艺路线、晶型及其制备方法
本申请主张如下优先权：
CN201811565301.3，申请日2018.12.20。
技术领域
本发明公开了式(IV)化合物的工艺路线、晶型及其制备方法，还包括所述晶型在制备治疗与SSAO相关疾病药物中的应用。
背景技术
在包括人类的大多数生物体中，两个族的哺乳动物胺氧化酶代谢各种内源产生的或从外源来源吸收的单胺-、二胺-和多胺。这些包括存在于大多数细胞类型的线粒体中并且使用共价结合的黄素腺嘌呤二核苷酸(FAD)作为辅助因子的单胺氧化酶(MAO-A和MAO-B)。多胺氧化酶是氧化脱氨基精胺和亚精胺的另一种FAD-依赖性胺氧化酶。SSAO/VAP-1属于依赖铜的第二族并且使用除了FAD之外的诸如氧化酪氨酸残基(简称为TPQ或LTQ)的其他辅助因子。MAO和SSAO/VAP-1氧化脱氨基包括单胺如多巴胺、酪胺和苄胺的一些常见底物。SSAO/VAP-1还氧化内源性甲基胺和氨基丙酮。
氨基脲敏感性胺氧化酶(SSAO)，还被称为伯胺氧化酶、血浆胺氧化酶和苄胺氧化酶在结构上与血管粘附蛋白-1(VAP-1)相同。SSAO/VAP-1用于描述该蛋白。
最初通过一些化合物抑制其酶活性的能力定义这些酶中的一些。例如，MAO-A被氯吉兰选择性抑制、MAO-B被L-苄甲炔胺选择性抑制，虽然氯吉兰或L-苄甲炔胺都不可抑制SSAO/VAP-1的胺氧化酶活性。SSAO/VAP-1可被氨基脲抑制，因此命名氨基脲敏感性胺氧化酶。
SSAO/VAP-1是胞外酶，其包含非常短的胞质尾、单一跨膜结构域和大的包含用于胺氧化酶活性的活性中心的高度糖基化的细胞外结构域。SSAO/VAP-1还以在一些动物的血浆中循环的溶解形式存在。已经证明该形式是膜结合的SSAO/VAP-1的断裂产物。
SSAO/VAP-1似乎具有两种生理学功能：第一种是上述胺氧化酶活性且第二种是细胞粘附活性。两种活性与炎性过程有关。SSAO/VAP-1被证明在来自炎症部位的循环的炎性细胞的外渗中发挥重要作用。VAP-1抗体被证实通过阻滞SSAO/VAP-1蛋白的粘附部位来减弱炎性过程，并且提供了大量的体外和体内敲除证据，现在清楚SSAO/VAP-1是重要的炎症的细胞介体。
WO2013163675报道了化合物PXS-4728A，其结构如下。
Figure PCTCN2019127155-appb-000001
发明内容
本发明提供了式(IV)化合物的A晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：9.05±0.2°、12.34±0.2°、22.52±0.2°。
Figure PCTCN2019127155-appb-000002
本发明的一些方案中，上述式(IV)化合物的A晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：9.05±0.2°、12.34±0.2°、16.60±0.2°，17.17±0.2°，17.83±0.2°，20.82±0.2°，22.52±0.2°，26.03±0.2°。
本发明的一些方案中，上述式(IV)化合物的A晶型，其XRPD图谱如图1所示。
本发明的一些方案中，上述式(IV)化合物的A晶型，其XRPD图谱解析数据如表1所示。
表1A晶型XRPD图谱解析数据
Figure PCTCN2019127155-appb-000003
本发明的一些方案中，上述式(IV)化合物的A晶型，其差示扫描量热曲线在223.0℃±3.0℃处具有吸热峰的峰值。
本发明的一些方案中，上述式(IV)化合物的A晶型，其DSC图谱如图2所示。
本发明的一些方案中，上述式(IV)化合物的A晶型，其热重分析曲线在150.0℃±3℃时失重达3.78％。
本发明的一些方案中，上述式(IV)化合物的A晶型，其TGA图谱如图3所示。
本发明还提供了式(IV)化合物的A晶型的制备方法，包括将任意一种形式的式(IV)化合物加入到酯类、醚类有机混合溶剂中打浆制得，其中，打浆温度选自20℃～40℃。
本发明的一些方案中，上述酯类溶剂选自乙酸乙酯，醚类溶剂选自甲基叔丁基谜。
本发明的一些方案中，上述打浆时间选自30小时～60小时。
本发明的一些方案中，上述式(IV)化合物与有机混合溶剂的重量体积比选自1:5～40。
本发明提还供了式(IV)化合物的B晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：11.27±0.2°、21.44±0.2°、22.32±0.2°。
本发明的一些方案中，上述式(IV)化合物的B晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：11.27±0.2°、12.46±0.2°、18.44±0.2°、21.44±0.2°、22.32±0.2°、25.51±0.2°、25.94±0.2°、26.49±0.2°。
本发明的一些方案中，上述式(IV)化合物的B晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：11.27±0.2°、12.46±0.2°、18.44±0.2°、20.03±0.2°、21.44±0.2°、22.32±0.2°、23.37±0.2°、24.19±0.2°、25.51±0.2°、25.94±0.2°、26.49±0.2°、28.12±0.2°。
本发明的一些方案中，上述式(IV)化合物的B晶型，其XRPD图谱如图4所示。
表2 B晶型XRPD图谱解析数据
Figure PCTCN2019127155-appb-000004
Figure PCTCN2019127155-appb-000005
本发明的一些方案中，上述式(IV)化合物的B晶型，其差示扫描量热曲线在221.9℃±3.0℃处具有吸热峰的峰值。
本发明的一些方案中，上述式(IV)化合物的B晶型，其DSC图谱如图5所示。
本发明的一些方案中，上述式(IV)化合物的B晶型，其热重分析曲线在150.0℃±3℃时失重达1.05％。
本发明的一些方案中，上述式(IV)化合物的B晶型，其TGA图谱如图6所示。
本发明还提供了式(IV)化合物的B晶型的制备方法，包括将任意一种形式的式(IV)化合物加入到酯类、醚类、醇类、丙酮、乙腈、正庚烷、水、有机混合溶剂以及水和有机混合溶剂中打浆制得，其中，打浆温度选自40℃～60℃。
本发明的一些方案中，上述式(IV)化合物的B晶型的制备方法，其中，酯类溶剂选自乙酸乙酯，醚类溶剂选自四氢呋喃和甲基叔丁基醚，醇类溶剂选自乙醇，有机混合溶剂选自体积比为95:5的甲基叔丁基醚和甲醇的混合溶剂以及体积比为95:5的甲基叔丁基醚和乙醇的混合溶剂，水和有机混合溶剂选自体积比为5:95的水和丙酮的混合溶剂、体积比为5:95的水和乙腈的混合溶剂以及体积比为5:95的水和四氢呋喃的混合溶剂。
本发明的一些方案中，上述式(IV)化合物的B晶型的制备方法，其中，打浆时间选自30小时～60小时。
本发明的一些方案中，上述式(IV)化合物的B晶型的制备方法，其中，式(IV)化合物与有机混合溶剂的重量体积比选自1:5～40。
本发明还提供了上述A晶型或B晶型在制备治疗SSAO相关疾病药物中的应用。
本发明的一些方案中，上述SSAO相关疾病为非酒精脂肪肝炎。
本发明还提供了式(IV)化合物的制备方法，
Figure PCTCN2019127155-appb-000006
其包括如下步骤：
Figure PCTCN2019127155-appb-000007
其中，
溶剂a选自醋酸；
试剂b选自盐酸。
本发明的一些方案中，上述式(IV)化合物的制备方法，其中，溶剂a与SM1的体积：质量为3.0～3.5：1，试剂b与SM1的体积：质量为3.0～10：1。
本发明的一些方案中，上述式(IV)化合物的制备方法，其中，控制反应内温为75-80℃。
本发明的一些方案中，上述式(IV)化合物的制备方法，其包含如下步骤：
Figure PCTCN2019127155-appb-000008
本发明的一些方案中，上述式(IV)化合物的制备方法，其中，试剂c选自吡啶；化合物D的制备为碱性条件下的水解反应；试剂d选自溴化钾，试剂e选自次氯酸钠；试剂f选自醋酸银。
技术效果
本发明式(IV)化合物的A晶型和B晶型具有良好的稳定性。式(IV)化合物和式(IV)化合物的B晶型在体外测试中表现出很强的抑制人重组VAP-1/SSAO酶的活性和抑制VAP-1/SSAO细胞的活性。
定义和说明
除非另有说明，本文所用的下列术语和短语旨在含有下列含义。一个特定的短语或术语在没有特别定 义的情况下不应该被认为是不确定的或不清楚的，而应该按照普通的含义去理解。当本文出现商品名时，旨在指代其对应的商品或其活性成分。
本发明的中间体化合物可以通过本领域技术人员所熟知的多种合成方法来制备，包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式，优选的实施方式包括但不限于本发明的实施例。
本发明具体实施方式的化学反应是在合适的溶剂中完成的，所述的溶剂须适合于本发明的化学变化及其所需的试剂和物料。为了获得本发明的化合物，有时需要本领域技术人员在已有实施方式的基础上对合成步骤或者反应流程进行修改或选择。
下面会通过实施例具体描述本发明，这些实施例并不意味着对本发明的任何限制。
本发明的化合物可以通过本领域技术人员所熟知的常规方法来确认结构，如果本发明涉及化合物的绝对构型，则该绝对构型可以通过本领域常规技术手段予以确证。例如单晶X射线衍射法(SXRD)，把培养出的单晶用Bruker D8 venture衍射仪收集衍射强度数据，光源为CuKα辐射，扫描方式：
Figure PCTCN2019127155-appb-000009
扫描，收集相关数据后，进一步采用直接法(Shelxs97)解析晶体结构，便可以确证绝对构型。
本发明所使用的所有溶剂是市售的，无需进一步纯化即可使用。
本发明采用下述缩略词：DMF代表二甲基甲酰胺；DCM代表二氯甲烷；DMSO二甲亚砜；MeOH代表甲醇；MsOH代表甲磺酸；EtOH代表乙醇；NaOH代表氢氧化钠；TEA代表三乙胺；HCl代表盐酸；Tol代表甲苯；KOH代表氢氧化钾；TEBAC代表苄基三乙基氯化铵；KBr代表溴化钾；NaHCO 3代表碳酸氢钠；NaClO代表次氯酸钠；TEMPO代表2,2,6,6-四甲基哌啶氧化物；Na 2S 2O 3代表硫代硫酸钠；AcOH代表醋酸；NMP代表N-甲基吡咯烷酮；AgOAc代表醋酸银；2-MeTHF代表2-甲基四氢呋喃；DAST代表二乙胺基三氟化硫；TBSCl代表叔丁基二甲基氯硅烷；DMP代表邻苯二甲酸二甲酯；NaHMDS代表双(三甲基硅基)氨基钠；TBAF代表四丁基氟化铵；MgEtBr代表乙基溴化镁。
化合物依据本领域常规命名原则或者
Figure PCTCN2019127155-appb-000010
软件命名，市售化合物采用供应商目录名称。
本发明粉末X-射线衍射(X-ray powder diffractometer,XRPD)方法
仪器型号：布鲁克D8 advance X-射线衍射仪
测试方法：大约10～20mg样品用于XRPD检测。
详细的XRPD参数如下：
光管：Cu,kα,
Figure PCTCN2019127155-appb-000011
光管电压：40kV，光管电流：40mA
发散狭缝：0.60mm
探测器狭缝：10.50mm
防散射狭缝：7.10mm
扫描范围：4-40deg
步径：0.02deg
步长：0.12秒
样品盘转速：15rpm
本发明差热分析(Differential Scanning Calorimeter,DSC)方法
仪器型号：TA Q2000差示扫描量热仪
测试方法：取样品(约1mg)置于DSC铝锅内进行测试，在50mL/min N 2条件下，以10℃/min的升温速率，加热样品从30℃(室温)到300℃(或350℃)。
本发明热重分析(Thermal Gravimetric Analyzer,TGA)方法
仪器型号：TA Q5000IR热重分析仪
测试方法：取样品(2～5mg)置于TGA铂金锅内进行测试，在25mL/min N 2条件下，以10℃/min的升温速率，加热样品从室温到350℃或失重20％。
本发明X-射线单晶衍射方法
仪器型号：Rigaku Oxford Diffraction XtaLAB Synergy-S
测试方法：样品在室温条件下溶解于1mL二氯甲烷/甲醇(1:1)中。将样品溶液置于4mL半密封样品瓶中，在室温下缓慢挥发。第二天得到无色块状晶体。衍射实验温度T＝99.99(11)K。
仪器参数：
Rigaku Oxford Diffraction XtaLAB Synergy four-circle diffractometer equipped with a HyPix-6000HE area detector.
Cryogenic system:Oxford Cryostream 800
Cu:
Figure PCTCN2019127155-appb-000012
50W,Micro focus source with multilayer mirror(μ-CMF).
Distance from the crystal to the CCD detector:d＝35mm
Tube Voltage:50kV
Tube Current:1mA
附图说明
图1为式(IV)化合物的A晶型的Cu-Kα辐射的XRPD谱图。
图2为式(IV)化合物的A晶型的DSC图。
图3为式(IV)化合物的A晶型的TGA图。
图4为式(IV)化合物的B晶型的Cu-Kα辐射的XRPD谱图。
图5为式(IV)化合物的B晶型的DSC图。
图6为式(IV)化合物的B晶型的TGA图。
图7为式(IV)化合物的立体结构椭球图。
具体实施方式
为了更好的理解本发明的内容，下面结合具体实施例来做进一步的说明，但具体的实施方式并不是对本发明的内容所做的限制。
实施例1：式(IV)化合物的制备
Figure PCTCN2019127155-appb-000013
步骤1：
在洁净干燥的50L三口瓶加入MeOH(2.5L)，开启搅拌，随后加入SMA(572g,4.80mol)。冰水浴， 控制体系温度在0-30℃，向体系中缓慢滴加乙酰氯(2.26kg,28.81mol,2.06L)该阶段放热剧烈，注意控制滴加速度。滴加3小时滴加完毕。加毕，移去冰水浴，控制体系温度在20-30℃下继续搅拌16小时。停止搅拌，反应液转移至桌面抽滤器过滤中抽滤，用1L MeOH淋洗一次，收集滤饼。滤饼抽干后，转移至洁净的托盘中，室温晾置>24小时。收料，得到化合物A。
1H NMR(399MHz,DMSO-d 6)δ11.18(br s,1H),10.59-10.53(m,1H),8.08-7.97(m,2H),7.04-6.96(m,2H),4.24(s,3H)。
步骤2：
将化合物A(500g,2.66mol HCl)溶于DCM(3L)。加入TEA(404.49g,4.00mol,556.39mL)搅拌30分钟。随后加入吡啶(421.59g,5.33mol,430.19mL)至上述体系。控制体系温度在10-30℃缓慢滴加SMB(612.87g,5.86mol,532.93mL)。反应在20℃下搅拌1小时。加水1.5L，随后加入0.5M HCl(1.4L)调节体系pH至5～6，水相用1.5L DCM萃取一次，合并有机相，加入水4L洗涤，分液有机相用饱和食盐水3L洗涤，分液。有机相用无水硫酸钠干燥，减压浓缩，得到粗产品。粗产品加入2200mL(正庚烷：乙酸乙酯＝10:1)25℃打浆4小时，过滤，得到化合物B。
1H NMR(400MHz,CDCl 3)δ7.77-7.69(m,2H),7.19-7.12(m,2H),3.89(s,3H),1.89-1.80(m,1H),1.72-1.62(m,1H),1.21-1.14(m,2H),1.10-1.01(m,4H),0.89(qd,J＝3.7,7.7Hz,2H)。
步骤3：
在干燥的三口瓶中加入SMC(230.94g,2.09mol)和甲苯(3000mL)。随后加入TEA(211.32g,2.09mol,290.67mL,1eq)，开启搅拌，升温至外温80℃-90℃，内温稳定在72℃。分批加入化合物B(600g,2.09mol)(加入一半时升温至78℃)，加料过程控制温度在70-80℃之间。加入后内温稳定在74℃，搅拌2小时。加入水2L，分液。水相用乙酸乙酯(1L*2)萃取，有机相合并。有机相用饱和食盐水(2L*2)洗涤，分液。有机相用无水硫酸钠干燥，减压浓缩得到粗产品。粗产品加入2L(正庚烷：乙酸乙酯＝10:1)25℃打浆2小时。得到化合物C。
1H NMR(400MHz,DMSO-d 6)δ7.93(d,J＝8.6Hz,2H),7.17(d,J＝8.8Hz,2H),4.90-4.77(m,1H),2.22-2.12(m,1H),1.95-1.83(m,1H),1.46(d,J＝6.6Hz,6H),1.04(dtd,J＝3.0,5.0,9.8Hz,6H),1.00-0.96(m,2H)。
步骤4：
分批次，在干燥的50L高低温循环浴中加入EtOH(10L)，随后向釜中加入化合物C(3.3kg，10.6mol)，开启搅拌。控制内温在0-40℃，加入NaOH(0.860kg，21.5mol)和水(10L)的混合溶液。加料过程升温但不剧烈。加毕，反应在25-35℃下搅拌17-18小时。控制反应液温度，向反应液中加入12N HCl调至pH＝3-4，有固体析出。反应液转移至桌面式过滤器中，过滤，收集滤饼，得粗产品。合并5批次粗产品20kg，用2体积乙腈25℃打浆纯化1小时，混合液通过桌面式过滤器过滤，滤饼用乙腈淋洗，收集滤饼。转移至洁 净托盘中，自然晾干>24小时。得到化合物D。
1H NMR(400MHz,DMSO-d 6)δ9.60(s,1H),7.73(d,J＝8.7Hz,2H),6.78(d,J＝8.5Hz,2H),4.81(quin,J＝6.6Hz,1H),2.20-2.09(m,1H),1.44(d,J＝6.5Hz,6H),1.09-1.00(m,2H),0.98-0.92(m,2H)。
步骤5：
在干燥的50L高低温循环浴中加入环氧氯丙烷(6.600kg)。随后加入DMSO(6L)，开启搅拌，加入化合物D(3.200kg)，用DMSO(3L)冲洗余料。控制内温在(20-30)℃，加入KOH(0.889kg)，略有升温，但是不明显。加毕，内温稳定在(27-30)℃，搅拌18小时。将反应液放出，向釜内加水8L，开启搅拌，控制温度在0-30℃，将反应液通过蠕动泵缓慢转移至釜中。随后加入甲基叔丁基醚8L，搅拌15分钟，静置15分钟，分液，收集有机相，水相再次萃取，收集有机相。两次有机相合并。搅拌下，向有机相加入无水硫酸钠1kg干燥有机相，减压浓缩，控制水浴锅温度＜45℃，旋蒸真空表压力＜-0.08MPa浓缩。油泵进一步减压浓缩，控制水浴锅温度<70℃，旋蒸真空表压力＜-0.08MPa浓缩，至理论量的105％，浓缩液直接用于下一步反应。得到化合物E。
1H NMR(399MHz,DMSO-d 6)δ7.88-7.80(m,2H),6.99(d,J＝8.8Hz,2H),4.83(quin,J＝6.6Hz,1H),4.35(dd,J＝2.6,11.4Hz,1H),3.85(dd,J＝6.4,11.2Hz,1H),3.36-3.34(m,1H),2.85(t,J＝4.6Hz,1H),2.72(dd,J＝2.6,4.8Hz,1H),2.23-2.07(m,1H),1.45(d,J＝6.6Hz,6H),1.07-1.00(m,2H),0.99-0.94(m,2H)。
步骤6：
将化合物E(3.86kg)溶于异丙醇(15L)，混合溶液加入到干燥的50L高低温循环浴中，开启搅拌。加入TEBAC(0.592kg)，随后加入SME(2.295kg)，最后加入5L异丙醇，冲洗反应釜壁。控制温度在80-90℃，反应22小时。向体系中中加入15L正庚烷，降低搅拌速度，缓慢降温，控制温度20-25℃，搅拌1小时，析出固体。用蠕动泵将反应液转移至桌面式过滤器，抽滤，滤饼用正庚烷5L洗涤。收集滤饼至洁净托盘，自然晾干>24小时。得到化合物F。
1H NMR(400MHz,DMSO-d 6)δ7.90-7.83(m,4H),7.81(d,J＝8.8Hz,2H),6.90(d,J＝8.9Hz,2H),5.40(d,J＝5.5Hz,1H),4.88-4.75(m,1H),4.25-4.11(m,1H),3.99(br s,2H),3.73(s,2H),2.22-2.07(m,1H),1.45(d,J＝6.7Hz,6H),1.07-1.00(m,2H),0.96(br s,2H)。
步骤7：
取化合物F(3.01kg)溶于DCM(15L)，混合溶液加入干燥的高低温循环浴，开启搅拌。加入KBr(0.97kg)，随后加入NaHCO 3(2.83kg)和H 2O(100mL)的混合溶液，然后加入TEMPO(54.00g)。控制内温0-5℃，滴加NaClO(16.4kg,6％质量含量)。控制体系温度在20-25℃以下，搅拌2小时。停止反应，静置15分钟，分液，收集有机相，加入饱和Na 2S 2O 3(aq)洗涤(15L)，搅拌5分钟，静置15分钟，分液。有机相用无水Na 2SO 4干燥，过滤，减压浓缩，控制水浴锅温度＜45℃，旋蒸真空表压力＜-0.08MPa，浓缩至有固体析出。加入乙酸乙酯5L，转移至50L球釜，再加入10L正庚烷，打浆16小时。过滤，收集滤饼至洁 净托盘，自然晾干>24小时。得到化合物G。
1H NMR(399MHz,DMSO-d 6)δ7.95-7.87(m,4H),7.84(d,J＝8.8Hz,2H),7.00(d,J＝8.8Hz,2H),5.13(s,2H),4.90-4.80(m,1H),4.78(s,2H),2.22-2.12(m,1H),1.46(d,J＝6.6Hz,6H),1.08-1.01(m,2H),1.00-0.93(m,2H)。
步骤8：
0℃下，向SMF(46.31g,191.23mmol,38.92mL)的2-MeTHF(200mL)溶液中，加入MgEtBr(3M,63.74mL)，所得在0-10℃反应20分钟，然后加入化合物G(50g,112.49mmol)，加料完毕后，反应液升温至40℃反应1小时。向反应液中加入饱和柠檬酸溶液(200mL)，搅拌10分钟，分出有机相。有机相用1M NaOH水溶液洗涤(200mL)，搅拌10分钟，分出有机相。有机相旋干，100mL甲基叔丁基醚：异丙醇＝1:1(2V)25℃打浆16小时，过滤收集滤饼。(有机相直接旋干产品结块，采用异丙醇小量替换2-MeTHF策略)。得到SM1。
1H NMR(399MHz,DMSO-d 6)δ7.87-7.79(m,4H),7.73(d,J＝8.8Hz,2H),6.73(d,J＝9.2Hz,2H),4.98(d,J＝0.9Hz,2H),4.87-4.77(m,1H),4.58(d,J＝2.6Hz,2H),4.26(q,J＝7.0Hz,2H),2.20-2.11(m,1H),1.44(d,J＝6.6Hz,6H),1.22(t,J＝7.0Hz,3H),1.07-1.00(m,2H),0.98-0.92(m,2H)。
步骤9：
20-25℃下，将AcOH(8L)加入到干燥洁净的50L夹套反应釜中，搅拌下加入SM1(2450g，4.60mol)，体系成混悬体系。向体系中加入配制好的6M HCl(8L)溶液，升温至90-95℃(控制内温在75-80℃)，上述混合液在90-95℃下反应16小时。将三颈烧瓶转至0℃冰水浴中下降至内温0-10℃。将反应体系转移至桌面过滤器抽滤，得到滤饼，用水(2L)洗涤滤饼两次，继续抽滤至无滤液产生。二次向此三颈烧瓶中加入AcOH(12L)，开启搅拌，随后加入滤饼及配制好的6M HCl(12L)溶液，升温至90-95℃(控制内温在75-80℃)，上述混合液在90-95℃下反应48h，取样，当SM1残留量<2.0％时，停止反应。反应液冷却到0-10℃，过滤，滤饼用5L水洗涤滤饼两次，得到粗品。将粗品加入到乙腈(8L)中，升温到50-55℃，搅拌3小时。趁热过滤，收集滤饼，滤饼置于25-30℃的通风橱中干燥24小时，得到化合物1。
1H NMR(400MHz,DMSO-d 6)δ7.86-7.80(m,4H),7.80-7.75(m,2H),6.76(d,J＝8.8Hz,2H),5.02(s,2H),4.92-4.82(m,2H),4.56(d,J＝2.4Hz,2H),2.28-2.15(m,1H),1.45(d,J＝6.5Hz,5H),1.12-1.04(m,4H)。
步骤10：
20-25℃下将NMP(1.34L)加入到5L三口烧瓶中，搅拌下加入化合物化合物1(1.34kg,2.66mol)，体系成混悬体系，将体系加热至135-140℃(控制内温在120-125℃)。向上述混合液中加入AgOAc(433.98g,2.66mol)，所得在135-140℃(控制内温在120-125℃)反应16小时。补加0.2eq AgOAc(88.80g,0.48mol)，继续保持135-140℃(控制内温在120-125℃)反应结束。反应液冷却到20-25℃，向反应液中加入乙酸乙酯(6.85L)进行稀释，加入活性炭(543g)和硅藻土(543g)，搅拌20分钟后垫硅胶(543g)过滤，用乙酸 乙酯(6.85L)洗涤滤饼三次。滤液用10％硫代硫酸钠溶液(6.85L)洗涤两次，用0.5M的氢氧化钠溶液(6.85L)洗涤一次，清水(6.85L)洗涤两次，将有机相减压旋干得到粗品。20-25℃下，将乙酸乙酯(2.64L)，正庚烷(13.2L)加入到25L圆桶中，随后加入粗品(2.64kg,5.73mol)，20-25℃下打浆搅拌16小时，过滤收集滤饼，得到化合物2。
1H NMR(399MHz,DMSO-d 6)δ7.91-7.79(m,4H),7.70(d,J＝8.8Hz,2H),7.38-7.08(m,1H),6.73-6.65(m,2H),4.82(quin,J＝6.6Hz,1H),4.49-4.38(m,4H),2.21-2.09(m,1H),1.44(d,J＝6.6Hz,6H),1.06-1.00(m,2H),0.97-0.91(m,2H)。
步骤11：
20-25℃下将2-MeTHF溶液(6L)加入到50L高低温夹套釜中，搅拌下加入化合物2(2kg，4.343mol)，体系溶清，向体系中加入水(3L)及乙醇胺(2.652kg，43.43mol)，升温至75-80℃(控制体系内温为65-70℃)，上述混合液在75-80℃(控制体系内温为65-70℃)下反应16小时。反应液冷却至20-25℃，进行分液，收集有机相，水相用2-MeTHF溶液(6L)萃取一次，将有机相合并减压旋干。粗品用3N盐酸(6L)溶清，水溶液用甲基叔丁基醚(6L)萃取一次，用乙酸乙酯(6L)萃取两次。用1M的氢氧化钠溶液调节水溶液至pH>10，用甲基叔丁基醚(6L)萃取两次，合并有机相，过滤有机相中的不溶物，将有机相减压旋干。有机相用2-MeTHF溶液(6L)溶清，0.5M的氢氧化钠溶液(6L)洗涤一次，水(6L)洗两次，收集有机相，将有机相减压旋干。将粗品加入到5L单口瓶中，随后加入乙酸乙酯(2.86L)，异丙醇(2.86L)，控制外温70-75℃，搅拌溶解10分钟，趁热过滤，除掉不溶物收集滤液。在70-75℃下，向滤液中加入乙酸乙酯(1.43L)，异丙醇(1.43L)，滴加盐酸异丙醇溶液(1.086L)，滴加完毕后，降温至50-55℃，在50-55℃下反应2小时。停止反应，反应液冷却至20-25℃，过滤，滤饼用乙酸乙酯(1.43L)洗涤两次，得到粗品。20-25℃下将固体，乙酸乙酯(4.29L)加入到3L单三口烧瓶中，在20-25℃下搅拌16小时。过滤得到固体。20-25℃下将固体，乙酸乙酯(2.15L)，甲醇(2.15L)加入到3L三口烧瓶中，在20-25℃下搅拌16小时。过滤得到式(IV)化合物。
1H NMR(400MHz,DMSO-d 6)δ8.46(br s,3H),8.00(d,J＝8.8Hz,2H),7.47-7.19(m,1H),7.10(d,J＝8.9Hz,2H),4.92(td,J＝6.6,13.1Hz,1H),4.71(d,J＝3.1Hz,2H),3.59(br d,J＝4.6Hz,2H),2.36-2.26(m,1H),1.47(d,J＝6.5Hz,5H),1.22(br d,J＝2.6Hz,2H),1.17-1.09(m,2H)。
实施例2：式(IV)化合物的单晶X射线衍射检测分析
单晶培养过程：样品在室温条件下溶解于1ml二氯甲烷/甲醇(1:1)中。将样品溶液置于4ml半密封样品瓶中，在室温下缓慢挥发。第二天得到无色块状晶体。式(IV)化合物立体结构椭球图见附图7。式(I)化合物晶体结构数据和参数见表3、4、5、6和7。
表3.式(IV)化合物的晶体数据
Figure PCTCN2019127155-appb-000014
表4.式(IV)化合物晶体的原子坐标(×10 4)和等价各向同性移位参数
Figure PCTCN2019127155-appb-000015
Figure PCTCN2019127155-appb-000016
Figure PCTCN2019127155-appb-000017
表5.式(IV)化合物的键长
Figure PCTCN2019127155-appb-000018
Figure PCTCN2019127155-appb-000019
表6.式(IV)化合物的键角(°)
Figure PCTCN2019127155-appb-000020
Figure PCTCN2019127155-appb-000021
表7.式(IV)化合物的扭转角度(°)
Figure PCTCN2019127155-appb-000022
实施例3：式(IV)化合物的A晶型的制备
将式(IV)化合物(50mg)中加入乙酸乙酯(1mL)中，40℃打浆48小时，降温到20-25℃后过滤，收集固体，在40℃下真空干燥48小时，得到式(IV)化合物的A晶型。
实施例4：式(IV)化合物的B晶型的制备
将式(IV)化合物(50mg)中加入甲基叔丁基谜(1mL)中，50℃打浆48小时，降温到20-25℃后过滤，收集固体，在40℃下真空干燥48小时，得到式(IV)化合物的B晶型。
实施例5：式(IV)化合物的B晶型的稳定性研究
用电子天平准确称取(IV)化合物的B晶型每份60mg样品(每个稳定性测试条件平行称量3个样品)，分别置于干燥洁净的5mL烧杯中，摊成薄薄一层，将铝箔纸扎孔，并盖到烧杯上，用皮筋固定，将烧杯放置于各个稳定性条件环境中，等待考察时间点取样分析。分别考察样品在60℃(5天、10天)、25℃/92.5％RH(5天、10天)、40℃/75％RH(1月、2月、3月)、60℃/75％RH(1月、2月)及光照(10天)等条件下的稳定性情况。使用X射线粉末衍射(XRPD)对各条件下的固体进行表征。
表8.式(IV)化合物B晶型的固体稳定性试验结果
Figure PCTCN2019127155-appb-000023
结论：式(IV)化合物的B晶型在高温、高湿、强光照条件具有良好的稳定性。
实验例1：体外评价
人VAP-1酶活性测定试验:
采用
Figure PCTCN2019127155-appb-000024
Red Monoamine Oxidase试剂盒(Invitrogen#A12214)测定样品对VAP-1酶活性抑制作用。384孔板中加入100nL的经梯度稀释的待测化合物(溶剂为DMSO)。加入25μL 10nM VAP-1酶溶液，室温孵育30分钟。加入VAP-1酶的底物混合物(200μM Amplex Red，1U/mL HRP,1mM Benzylamine)，室温孵育60分钟。孵育结束后用酶标仪Envision读取荧光信号(激发光波长530–560nm，发射光波长590nm)。用Prism软件分析去除背景信号后的荧光信号数值，计算出样品对VAP-1酶的IC 50。
表9.式(IV)化合物外筛选试验结果
Figure PCTCN2019127155-appb-000025
结论：式(IV)化合物和式(IV)化合物的B晶型在体外测试中表现出很强的抑制人重组VAP-1/SSAO酶的活性。
实验例2：VAP-1细胞活性测定试验
采用
Figure PCTCN2019127155-appb-000026
Red Monoamine Oxidase试剂盒(Invitrogen#A12214)测定样品对VAP-1酶活性抑制作用。
细胞准备
将培养好的HUVEC or CHO细胞以0.8M/孔的密度铺板到6孔板，置于37℃，5％CO 2培养箱中培养24h后用Lipo2000试剂和VAP-1/pCDNA(3.1)质粒转染细胞，5h后细胞换液(Lipo2000对细胞有毒)；24h后将细胞消化以25μl，10000cells/孔的密度铺板到384孔板中，6-7h用不含FBS的培养基对细胞换液并将细胞板置于37℃，5％CO 2培养箱中过夜培养。
化合物半抑制浓度检测
1)化合物的稀释：用100％DMSO进行4倍梯度连续稀释，稀释10个点，待测化合物起始浓度为0.5mM(终浓度为1μM)；用ECHO转移100nl化合物溶液于384孔的细胞检测板中。阴性对照孔：100nl的DMSO；背景对照孔：100nl DMSO+25μl的培养基。
2)室温避光反应30min。
3)Amplex Red试剂+HRP+苄胺底物工作液的配制：Amplex Red试剂+HRP+苄胺底物工作液(200μM Amplex Red试剂+1U/mL HRP+1mM苄胺)：取45μl的20mM Amplex Red试剂母液、22.5μl的200U/ml辣根过氧化物酶(HRP)母液和45μL的100mM苄胺，加入4.3875ml的1X反应缓冲液中。
4)30min后，取25μL的底物工作液，加至384孔板中，终浓度分别为100μM Amplex Red试剂+0.5U/mL HRP+0.5mM苄胺。
5)室温避光反应60min，用Envision测定荧光值：激发波为535nm，发射波为590nm。
6)抑制率计算公式：％抑制率＝(1-(扣除背景的试验孔-扣除背景的阳性对照孔)/(扣除背景的阴性对照孔-扣除背景的阳性对照孔))*100
7)用Prism分析数据。计算出样品对VAP-1细胞的IC 50。
表10.本发明化合物体外筛选试验结果
Figure PCTCN2019127155-appb-000027
Figure PCTCN2019127155-appb-000028
结论：式(IV)化合物及式(IV)化合物的B晶型在体外测试中表现出很强的抑制VAP-1/SSAO细胞的活性。

Claims (30)

  1. 式(IV)化合物的A晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：9.05±0.2°、12.34±0.2°、22.52±0.2°。
    Figure PCTCN2019127155-appb-100001
  2. 根据权利要求1所述式(IV)化合物的A晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：9.05±0.2°、12.34±0.2°、16.60±0.2°，17.17±0.2°，17.83±0.2°，20.82±0.2°，22.52±0.2°，26.03±0.2°。
  3. 根据权利要求2所述式(IV)化合物的A晶型，其XRPD图谱如图1所示。
  4. 根据权利要求1～3任意一项所述式(IV)化合物的A晶型，其差示扫描量热曲线在223.0℃±3.0℃处具有吸热峰的峰值。
  5. 根据权利要求4所述式(IV)化合物的A晶型，其DSC图谱如图2所示。
  6. 根据权利要求1～3任意一项所述式(IV)化合物的A晶型，其热重分析曲线在150.0℃±3℃时失重达3.78％。
  7. 根据权利要求6所述式(IV)化合物的A晶型，其TGA图谱如图3所示。
  8. 式(IV)化合物的A晶型的制备方法，包括将任意一种形式的式(IV)化合物加入到酯类、醚类溶剂中打浆制得其中，打浆温度选自20℃～40℃。
  9. 根据权利要求8所述的制备方法，其中，酯类溶剂选自乙酸乙酯，醚类溶剂选自甲基叔丁基谜。
  10. 根据权利要求8所述的制备方法，其中，打浆时间选自30小时～60小时。
  11. 根据权利要求8所述的制备方法，其中，式(IV)化合物与有机混合溶剂的重量比选自1:5～40。
  12. 式(IV)化合物的B晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：11.27±0.2°、21.44±0.2°、22.32±0.2°。
  13. 根据权利要求12所述式(IV)化合物的B晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：11.27±0.2°、12.46±0.2°、18.44±0.2°、21.44±0.2°、22.32±0.2°、25.51±0.2°、25.94±0.2°、26.49±0.2°。
  14. 根据权利要求13所述式(IV)化合物的B晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：11.27±0.2°、12.46±0.2°、18.44±0.2°、20.03±0.2°、21.44±0.2°、22.32±0.2°、23.37±0.2°、24.19±0.2°、25.51±0.2°、25.94±0.2°、26.49±0.2°、28.12±0.2°。
  15. 根据权利要求14所述式(IV)化合物的B晶型，其XRPD图谱如图4所示。
  16. 根据权利要求12～15任意一项所述式(IV)化合物的B晶型，其差示扫描量热曲线在221.9℃±3.0℃处具有吸热峰的峰值。
  17. 根据权利要求16所述式(IV)化合物的B晶型，其DSC图谱如图5所示。
  18. 根据权利要求12～15任意一项所述式(IV)化合物的B晶型，其热重分析曲线在150.0℃±3℃时失重达1.05％。
  19. 根据权利要求18所述式(IV)化合物的B晶型，其TGA图谱如图6所示。
  20. 式(IV)化合物的B晶型的制备方法，包括将任意一种形式的式(IV)化合物加入到酯类、醚类、醇类、丙酮、乙腈、正庚烷、水、有机混合溶剂以及水和有机混合溶剂中打浆制得，其中，打浆温度选自40℃～60℃。
  21. 根据权利20所述式(IV)化合物的B晶型的制备方法，其中，酯类溶剂选自乙酸乙酯，醚类溶剂选自四氢呋喃和甲基叔丁基醚，醇类溶剂选自乙醇，有机混合溶剂选自体积比为95:5的甲基叔丁基醚和甲醇的混合溶剂以及体积比为95:5的甲基叔丁基醚和乙醇的混合溶剂，水和有机混合溶剂选自体积比为5:95的水和丙酮的混合溶剂、体积比为5:95的水和乙腈的混合溶剂以及体积比为5:95的水和四氢呋喃的混合溶剂。
  22. 根据权利19所述式(IV)化合物的B晶型的制备方法，其中，打浆时间选自30小时～60小时。
  23. 根据权利19所述式(IV)化合物的B晶型的制备方法，其中，式(IV)化合物与有机混合溶剂的重量体积比选自1:5～40。
  24. 根据权利要求1～7任意一项所述的A晶型或根据权利要求12～19任意一项所述的B晶型在制备治疗SSAO相关疾病药物中的应用。
  25. 根据权利要求24所述的应用，其中SSAO相关疾病为非酒精脂肪肝炎。
  26. 式(IV)化合物的制备方法，
    Figure PCTCN2019127155-appb-100002
    其包括如下步骤：
    Figure PCTCN2019127155-appb-100003
    其中，
    溶剂a选自醋酸；
    试剂b选自盐酸。
  27. 根据权利要求26所述式(IV)化合物的制备方法，其中，溶剂a与SM1的体积：质量为3.0～3.5：1，试剂b与SM1的体积：质量为3.0～10：1。
  28. 根据权利要求27所述式(IV)化合物的制备方法，其中，控制反应内温为75-80℃。
  29. 根据权利要求28所述式(IV)化合物的制备方法，其包含如下步骤：
    Figure PCTCN2019127155-appb-100004
  30. 根据权利要求29所述式(IV)化合物的制备方法，其中，试剂c选自吡啶；化合物D的制备为碱性条件下的水解反应；试剂d选自溴化钾，试剂e选自次氯酸钠；试剂f选自醋酸银。
PCT/CN2019/127155 2018-12-20 2019-12-20 式(iv)化合物的工艺路线、晶型及其制备方法 Ceased WO2020125776A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES19897902T ES2981573T3 (es) 2018-12-20 2019-12-20 Ruta de procedimiento del compuesto de fórmula (IV), forma cristalina y método de preparación para el mismo
JP2021536243A JP7245911B2 (ja) 2018-12-20 2019-12-20 式（ｉｖ）で表される化合物の製造工程経路、結晶形及びその製造方法
CN201980066989.7A CN112823154A (zh) 2018-12-20 2019-12-20 式(iv)化合物的工艺路线、晶型及其制备方法
US17/311,431 US12077513B2 (en) 2018-12-20 2019-12-20 Process route of compound of formula (IV), crystal form and preparation method therefor
KR1020217022942A KR102583801B1 (ko) 2018-12-20 2019-12-20 식(iv) 화합물의 공정 경로와 결정형, 및 이의 제조 방법
AU2019408509A AU2019408509B2 (en) 2018-12-20 2019-12-20 Process route of compound of formula (IV), crystal form and preparation method therefor
EP19897902.3A EP3901143B1 (en) 2018-12-20 2019-12-20 Process route of compound of formula (iv), crystal form and preparation method therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811565301 2018-12-20
CN201811565301.3 2018-12-20

Publications (1)

Publication Number Publication Date
WO2020125776A1 true WO2020125776A1 (zh) 2020-06-25

Family

ID=71102539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/127155 Ceased WO2020125776A1 (zh) 2018-12-20 2019-12-20 式(iv)化合物的工艺路线、晶型及其制备方法

Country Status (8)

Country Link
US (1) US12077513B2 (zh)
EP (1) EP3901143B1 (zh)
JP (1) JP7245911B2 (zh)
KR (1) KR102583801B1 (zh)
CN (1) CN112823154A (zh)
AU (1) AU2019408509B2 (zh)
ES (1) ES2981573T3 (zh)
WO (1) WO2020125776A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480073A (zh) * 2020-12-02 2021-03-12 武汉药明康德新药开发有限公司 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163675A1 (en) 2012-05-02 2013-11-07 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of ssao and uses thereof
WO2018158140A1 (en) * 2017-03-01 2018-09-07 Boehringer Ingelheim International Gmbh TRANSITION METAL-CATALYZED PROTODECARBOXYLATION OF α-HALO-ACRYLIC ACID DERIVATIVES
WO2018196677A1 (zh) * 2017-04-28 2018-11-01 四川科伦博泰生物医药股份有限公司 氟代烯丙胺衍生物及其用途
WO2018233633A1 (zh) * 2017-06-20 2018-12-27 南京明德新药研发股份有限公司 Ssao 抑制剂
WO2019024924A1 (zh) * 2017-08-04 2019-02-07 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2019241751A1 (en) * 2018-06-15 2019-12-19 Metacrine, Inc. Ssao inhibitors and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004166A2 (en) 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163675A1 (en) 2012-05-02 2013-11-07 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of ssao and uses thereof
WO2018158140A1 (en) * 2017-03-01 2018-09-07 Boehringer Ingelheim International Gmbh TRANSITION METAL-CATALYZED PROTODECARBOXYLATION OF α-HALO-ACRYLIC ACID DERIVATIVES
WO2018196677A1 (zh) * 2017-04-28 2018-11-01 四川科伦博泰生物医药股份有限公司 氟代烯丙胺衍生物及其用途
WO2018233633A1 (zh) * 2017-06-20 2018-12-27 南京明德新药研发股份有限公司 Ssao 抑制剂
WO2019024924A1 (zh) * 2017-08-04 2019-02-07 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2019241751A1 (en) * 2018-06-15 2019-12-19 Metacrine, Inc. Ssao inhibitors and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480073A (zh) * 2020-12-02 2021-03-12 武汉药明康德新药开发有限公司 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法
CN112480073B (zh) * 2020-12-02 2022-03-22 武汉药明康德新药开发有限公司 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法

Also Published As

Publication number Publication date
CN112823154A (zh) 2021-05-18
EP3901143A1 (en) 2021-10-27
JP2022514714A (ja) 2022-02-14
AU2019408509A1 (en) 2021-06-03
US20220024880A1 (en) 2022-01-27
AU2019408509B2 (en) 2022-02-10
KR102583801B1 (ko) 2023-09-26
KR20210109562A (ko) 2021-09-06
JP7245911B2 (ja) 2023-03-24
ES2981573T3 (es) 2024-10-09
EP3901143B1 (en) 2024-05-29
US12077513B2 (en) 2024-09-03
EP3901143A4 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
JP2950616B2 (ja) トリテルペン誘導体
CA2583660C (en) Indoline compound and process for producing the same
CA3106484C (en) A salt of an lsd1 inhibitor and its crystal form
RU2447081C2 (ru) Способ получения агониста a2a-аденозинового рецептора и его полиморфов
US8076362B2 (en) Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
WO2019029491A1 (zh) 一种(r)-2-(4-氯-2-甲基苯氧)丙酸辛酯阻根剂的制备方法
JP2013533298A (ja) ４−［−２−［［５−メチル−１−（２−ナフタレニル）−１ｈ−ピラゾール−３−イル］オキシ］エチル］モルホリン塩酸塩の固体形態
WO2020125776A1 (zh) 式(iv)化合物的工艺路线、晶型及其制备方法
WO1991012236A1 (en) Sulfonanilide derivative and medicine
JPS62155285A (ja) 生理活性物質ｋ−２５２の誘導体
JPH02275877A (ja) 光学活性なケテンジチオアセタール誘導体及びその製造方法
WO2019101058A1 (zh) 一种urat1抑制剂的晶型及其制备方法
US20250353845A1 (en) Thyroid hormone beta receptor agonist, crystal form, preparation method and use
HK40042804A (zh) 式(iv)化合物的工艺路线、晶型及其制备方法
TW400320B (en) A benzoylguanidine compound having Na&lt;+&gt;/H&lt;+&gt; exchanger inhibitory activity, its preparation processes and the pharmaceutical compositions comprising the same
RU2794977C2 (ru) Соль ингибитора lsd1 и её полиморфная форма
JPS6327467A (ja) γ−グルタミル−４−ニトロアニリド誘導体及びこれを用いるγ−グルタミルトランスペプチダ−ゼ活性測定法
US8309602B2 (en) Multi-substituted diarylanilines as non-nucleoside HIV reverse transcriptase inhibitors, and preparation and use thereof
CA1265160A (en) Gem-dihalo and tetrahalo-1,12-diamino-4,9-diaza- dodecanes
CN115947677A (zh) 一种药物前体化合物及其制备方法和应用
CN120698996A (zh) 含吡唑的三唑类抗真菌化合物及其制备方法与应用
CN119119078A (zh) 一种3,4-二氢-2H-色烯并[8,7-d]异噁唑衍生物的可药用盐及其结晶形式
JPS6048972A (ja) テトラヒドロナフタレン誘導体
MXPA98006951A (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic
JPS59137468A (ja) フエニルピリダジノン又はその誘導体の製造法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19897902

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019408509

Country of ref document: AU

Date of ref document: 20191220

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021536243

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217022942

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019897902

Country of ref document: EP

Effective date: 20210720